- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06282783
Studying Topiramate for Re-Activating the HIV-1 Reservoir (STAR)
A Phase I/II Clinical Trial Investigating the Effect of Topiramate on the Reactivation of the HIV-1 Reservoir in People Living With HIV on Antiretroviral Therapy
Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible, and then getting rid of it. This is called the 'shock and kill' approach.
So far, the drugs tested can find the virus, but they don't get rid of it completely. That's why there need to be new drugs that can do this more effectively. The Erasmus MC HIV Eradication Group (EHEG) has been testing new drugs in the lab and found a drug called topiramate can wake up the virus without harming the cells. The aim of this study is to test topiramate in people living with HIV.
Most of the people that participate in HIV cure studies are men, even though most people living with HIV around the world are women. Previous research has shown that men and women might respond differently to these treatments. So, in this study, topiramate will be investigated in both men and women. This could help us find a cure that works for everyone.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Rotterdam, Netherlands
- Erasmus Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented HIV-1, subtype B or C
- Aged 18 or over
- On ART for a minimum of 2 consecutive years and a maximum of 12 consecutive years
- HIV-1 RNA plasma level <30 copies/mL for at least two consecutive measurements prior to inclusion (viral blips with a detectable HIVRNA 30-200 c/mL preceded and followed by HIV-RNA <30 are allowed)
- CD4+ T cell count ≥200 cells/mm^3 at screening
- Able to understand the information and give informed consent
Exclusion Criteria:
- Any major acute medical condition requiring hospitalisation within the past 4 weeks.
- Presence of an active opportunistic infection that defines Acquired Immunodeficiency Syndrome (AIDS).
- Any medical condition deemed by the investigator to hinder compliance with the study treatment.
- The following laboratory values at the screening phase (available before baseline (T0)): hepatic transaminases (AST or ALT) ≥3 times the upper limit of normal (ULN), serum total bilirubin ≥3 times the ULN, estimated glomerular filtration rate (eGFR) ≤60 mL/min based on CKD-EPI, haemoglobin <6.5 mmol/L (males) or <6.0 mmol/L (females), leucocytes <2.5 x10^9/L, absolute neutrophil count <1000 cells/mm^3, thrombocytes <100 x10^9/L
- Active malignancy during the past year except for basal carcinoma of the skin, stage 0 cervical carcinoma, Kaposi Sarcoma treated with ART alone, or other indolent malignancies.
- Participants who are unwilling or unable to use barrier contraception during sexual intercourse during the study.
- History of suicide or suicidal ideation.
- History of ophthalmological medical problems leading to glaucoma or visual field disturbances (e.g. macula oedema). Refraction abnormalities that can be corrected by lenses are acceptable.
- History of any medical condition with a causal relationship with hyperammonemia.
- Participants using phenytoin, carbamazepine, digoxin, lithium, or valproic acid throughout the trial period.
- Any concurrent medicine use associated with hyperammonemia (e.g. valproic acid).
- Participants with active substance abuse.
- Participants who have registered allergies to the investigational medical product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Men
Sex assigned at birth, male Single dose of 400mg topiramate
|
Single dose of 400mg
|
Experimental: Women
Sex assigned at birth, female Single dose of 400mg topiramate
|
Single dose of 400mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of topiramate as measured by cell-associated HIV RNA
Time Frame: 24 hours
|
To assess the effect of topiramate on HIV reactivation in people living with HIV on ART
|
24 hours
|
Number of treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 7 days
|
To evaluate the clinical safety and tolerability of topiramate
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Influence of sex on the primary outcome measures
Time Frame: 24 hours
|
To evaluate the influence of sex on reactivation potential as measured by cell-associated HIV RNA, and safety and tolerability of topiramate as assessed by CTCAE v4.0
|
24 hours
|
The effect of topiramate on the size of the HIV reservoir measured by relevant assays
Time Frame: 24 hours
|
To assess the effect of topiramate on the size of the HIV reservoir
|
24 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-511532-27-00
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Topiramate
-
Johnson & Johnson Taiwan LtdCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Supernus Pharmaceuticals, Inc.Completed
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteTerminated
-
Montefiore Medical CenterOrtho-McNeil PharmaceuticalCompletedObsessive-compulsive DisorderUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...TerminatedObesity | Hypertriglyceridemia | Hyperlipidemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedEpilepsy | Seizures | Epilepsies, Partial